Photorefractive intrastromal corneal crosslinking for treatment of myopic refractive error: Findings from 12-month prospective study using an epithelium-off protocol

Autor: Matthias Elling, H. Burkhard Dick, Inga Kersten-Gomez
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
Refractive error
Visual acuity
Time Factors
genetic structures
Corneal Pachymetry
Riboflavin
Visual Acuity
law.invention
0302 clinical medicine
law
Myopia
Prospective Studies
Corneal pachymetry
Prospective cohort study
Photosensitizing Agents
medicine.diagnostic_test
Epithelium
Corneal
Photorefractive effect
Middle Aged
Corneal topography
Sensory Systems
Cross-Linking Reagents
Treatment Outcome
Female
Collagen
medicine.symptom
Adult
medicine.medical_specialty
Corneal Stroma
Refraction
Ocular
Injections
03 medical and health sciences
Young Adult
Ophthalmology
medicine
Humans
Keratometer
business.industry
Corneal Topography
medicine.disease
eye diseases
Off-Protocol
030104 developmental biology
Photochemotherapy
030221 ophthalmology & optometry
Surgery
sense organs
business
Follow-Up Studies
Zdroj: Journal of cataract and refractive surgery. 44(4)
ISSN: 1873-4502
Popis: To assess the long-term effectiveness and safety of photorefractive intrastromal corneal crosslinking (CXL) in patients with low myopia.Ruhr University Eye Hospital, Bochum, Germany.Prospective case series.Healthy eyes with myopia were treated with photorefractive intrastromal CXL using the Mosaic System. Riboflavin 0.1% solution (VibeX Rapid) was topically administered, followed by 365 nm ultraviolet-A (30 mW/cmFourteen patients (24 eyes) with a mean age of 35.7 years were included. At all follow-ups, a statistically significant improvement in UDVA was observed (all P .001). The CDVA progressively improved from 1 month postoperatively and a statistically significant improvement was achieved at 12 months (P .001). The average reduction in manifest sphere was 0.90 diopter (D) ± 0.40 (SD) by 12 months. There were no significant differences in mean manifest sphere and MRSE at 3, 6, or 12 months. Compared with baseline, significant reductions in corneal curvature were also observed at all follow-ups (all P .05). There were no significant changes in endothelial cell density (P = 1.00) or number of cells (P = .95) at 12 months postoperatively, and no adverse events were reported.Photorefractive intrastromal CXL was a safe and efficacious treatment of refractive error in patients with low myopia.
Databáze: OpenAIRE
Externí odkaz: